MX2009009623A - Inidol y bencimidazol amidas como inhibidores de la dehidrogenasa hidroxi-esteroide. - Google Patents

Inidol y bencimidazol amidas como inhibidores de la dehidrogenasa hidroxi-esteroide.

Info

Publication number
MX2009009623A
MX2009009623A MX2009009623A MX2009009623A MX2009009623A MX 2009009623 A MX2009009623 A MX 2009009623A MX 2009009623 A MX2009009623 A MX 2009009623A MX 2009009623 A MX2009009623 A MX 2009009623A MX 2009009623 A MX2009009623 A MX 2009009623A
Authority
MX
Mexico
Prior art keywords
hydroxysteroid dehydrogenase
indole
compounds
dehydrogenase inhibitors
amides
Prior art date
Application number
MX2009009623A
Other languages
English (en)
Inventor
Henrik Sune Andersen
John Paul Kilburn
Gita Camilla Tejlgaard Kampen
Original Assignee
High Point Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by High Point Pharmaceuticals Llc filed Critical High Point Pharmaceuticals Llc
Publication of MX2009009623A publication Critical patent/MX2009009623A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describe el uso de amidas sustituidas para la modulación de la actividad del tipo 1 de la dehidrogenasa 11?-hidroxiesteroide (11?HSD1) y el uso de estos compuestos como composiciones farmacéuticas. También se describen una clase novedosa de amidas sustituidas, su uso en terapia, composiciones farmacéuticas que comprenden los compuestos, así como su uso en la fabricación de medicamentos. Los presentes compuestos son moduladores y más específicamente inhibidores de la actividad de 11?HSD1 y pueden ser útiles en el tratamiento de un rango de trastornos médicos en donde una concentración intracelular disminuida del glucocorticoide activo es deseable.
MX2009009623A 2007-03-09 2007-03-09 Inidol y bencimidazol amidas como inhibidores de la dehidrogenasa hidroxi-esteroide. MX2009009623A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2007/052219 WO2008110196A1 (en) 2007-03-09 2007-03-09 Indole- and benzimidazole amides as hydroxysteroid dehydrogenase inhibitors

Publications (1)

Publication Number Publication Date
MX2009009623A true MX2009009623A (es) 2009-09-21

Family

ID=38657008

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009009623A MX2009009623A (es) 2007-03-09 2007-03-09 Inidol y bencimidazol amidas como inhibidores de la dehidrogenasa hidroxi-esteroide.

Country Status (12)

Country Link
US (1) US8153798B2 (es)
EP (1) EP2134705A1 (es)
JP (1) JP2010520864A (es)
KR (1) KR20100015414A (es)
CN (1) CN101652359A (es)
AU (1) AU2007349112A1 (es)
BR (1) BRPI0721430A2 (es)
CA (1) CA2679866A1 (es)
EA (1) EA200970841A1 (es)
IL (1) IL200714A0 (es)
MX (1) MX2009009623A (es)
WO (1) WO2008110196A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003220222A1 (en) 2002-03-13 2003-09-29 Signum Biosciences, Inc. Modulation of protein methylation and phosphoprotein phosphate
JP2008515956A (ja) * 2004-10-12 2008-05-15 ノボ ノルディスク アクティーゼルスカブ １１β−ヒドロキシステロイドデヒドロゲナーゼ１型活性スピロ化合物
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
EP1843734A4 (en) 2005-02-03 2008-09-10 Signum Biosciences Inc COMPOSITIONS AND METHOD FOR INTENSIFYING COGNITIVE FUNCTIONS
EP1948190A2 (en) * 2005-11-01 2008-07-30 Transtech Pharma Pharmaceutical use of substituted amides
KR20080069189A (ko) * 2005-11-01 2008-07-25 트랜스테크 파르마, 인크. 치환된 아미드의 약학적 사용
EP2007722A1 (en) * 2006-03-21 2008-12-31 High Point Pharmaceuticals, LLC Adamantane derivatives for the treatment of the metabolic syndrome
EP2010479A1 (en) 2006-04-07 2009-01-07 High Point Pharmaceuticals, LLC 11 beta-hydroxysteroid dehydrogenase type 1 active compounds
JP2009539937A (ja) * 2006-06-16 2009-11-19 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー 置換型ピペリジンカルボキサミドの医薬的使用
CA2657078A1 (en) * 2006-07-13 2008-01-17 High Point Pharmaceuticals, Llc 11beta-hydroxysteroid dehydrogenase type 1 active compounds
EP1878721A1 (en) * 2006-07-13 2008-01-16 Novo Nordisk A/S 4-Piperidylbenzamides as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
CN101679217A (zh) 2007-02-23 2010-03-24 高点制药有限责任公司 作为11β-羟基类固醇脱氢酶抑制剂的N-金刚烷基苯甲酰胺
JP2010519242A (ja) * 2007-02-23 2010-06-03 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー 新規化合物
WO2008101885A1 (en) * 2007-02-23 2008-08-28 High Point Pharmaceuticals, Llc N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase
JP2010519240A (ja) * 2007-02-23 2010-06-03 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー １１−ベータ−ヒドロキシステロイドデヒドロゲナーゼの阻害剤としての、ｎ−アダマンチルベンズアミド
US20100056600A1 (en) * 2007-03-28 2010-03-04 Soren Ebdrup 11beta-hsd1 active compounds
ES2399912T3 (es) * 2007-04-11 2013-04-04 High Point Pharmaceuticals, Llc Nuevos compuestos
JP2010526777A (ja) * 2007-04-24 2010-08-05 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー 置換アミドの医薬用途
US9486441B2 (en) 2008-04-21 2016-11-08 Signum Biosciences, Inc. Compounds, compositions and methods for making the same
CN102223797A (zh) 2008-11-21 2011-10-19 高点制药有限责任公司 金刚烷基苯甲酰胺化合物
EP2243479A3 (en) 2009-04-20 2011-01-19 Abbott Laboratories Novel amide and amidine derivates and uses thereof
ES2350077B1 (es) 2009-06-04 2011-11-04 Laboratorios Salvat, S.A. Compuestos inhibidores de 11beta-hidroxiesteroide deshidrogenasa de tipo 1.
UY33001A (es) 2009-11-06 2011-05-31 Boehringer Ingelheim Int Derivados arilo y heteroarilcarbonilo de hexahidroindenopiridina y octahidrobenzoquinolina
WO2011068927A2 (en) * 2009-12-04 2011-06-09 Abbott Laboratories 11-β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11B-HSD1) INHIBITORS AND USES THEREOF
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2012015715A1 (en) 2010-07-27 2012-02-02 High Point Pharmaceuticals, Llc Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta hsd1 modulators
TWI537258B (zh) 2010-11-05 2016-06-11 百靈佳殷格翰國際股份有限公司 六氫茚并吡啶及八氫苯并喹啉之芳基－及雜環芳基羰基衍生物
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2018102552A1 (en) 2016-11-30 2018-06-07 Case Western Reserve University Combinations of 15-pgdh inhibitors with corcosteroids and/or tnf inhibitors and uses thereof
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
CN110573154A (zh) 2017-02-06 2019-12-13 卡斯西部储备大学 调节短链脱氢酶活性的组合物和方法

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1025881B (de) 1955-11-26 1958-03-13 Bayer Ag Verfahren zur Herstellung von Kondensationsprodukten
US2913454A (en) 1956-11-23 1959-11-17 Schenley Ind Inc Certain cycloalkanotriazoles, process and intermediates
US3723442A (en) 1970-12-31 1973-03-27 Yoshitomi Pharmaceutical 3-oxo-1-oxa-4,8-diazaspiro(4.5)decanes
US3784551A (en) 1971-07-08 1974-01-08 Yoshitomi Pharmaceutical 2-oxo-1,4-dioxa-8-azaspiro (4.5) decanes and related compounds
FR2456731A1 (fr) 1979-05-16 1980-12-12 Choay Sa Nouveaux derives substitues d'ary
US4350696A (en) 1980-03-08 1982-09-21 Pfizer Inc. Imidazole derivatives, process for their preparation and pharmaceutical compositions thereof
AU557300B2 (en) 1982-03-16 1986-12-18 Farmitalia Carlo Erba S.P.A. Substituted 1h-pyrazolo(1,5-alpha)pyrimidines and processes for their preparation
DE3445377A1 (de) 1983-12-23 1985-07-04 Sandoz-Patent-GmbH, 7850 Lörrach Carbocylische und heterocyclische carbonsaeureester und -amide von ueberbrueckten und nicht ueberbrueckten cyclischen stickstoffhaltigen aminen oder alkoholen
FI864875A0 (fi) 1986-11-28 1986-11-28 Orion Yhtymae Oy Nya farmakologiskt aktiva foereningar, dessa innehaollande kompositioner samt foerfarande och mellanprodukter foer anvaendning vid framstaellning av dessa.
US5283352A (en) 1986-11-28 1994-02-01 Orion-Yhtyma Oy Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same
YU213587A (en) 1986-11-28 1989-06-30 Orion Yhtymae Oy Process for obtaining new pharmacologic active cateholic derivatives
US4851423A (en) 1986-12-10 1989-07-25 Schering Corporation Pharmaceutically active compounds
US5272167A (en) 1986-12-10 1993-12-21 Schering Corporation Pharmaceutically active compounds
US5750532A (en) 1986-12-10 1998-05-12 Schering Corporation Pharmaceutically active compounds
US5225402A (en) 1989-02-10 1993-07-06 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
GB8904174D0 (en) 1989-02-23 1989-04-05 British Bio Technology Compounds
US5169850A (en) 1990-01-22 1992-12-08 American Cyanamid Company N-(dialkylamino)methylene)-substituted pyrazolo(1,5-a)-pyrimidine-3-carboxamides and N-(dialkylamino)methylene-substituted-4,5-dihydropyrazolo-(1,5-a)-pyrimidine-3-carboxamides
US5122539A (en) 1990-02-12 1992-06-16 Center For Innovative Technology Allosteric hemoglobin modifiers useful for decreasing oxygen affinity and preserving oxygen carrying capability of stored blood
US5382680A (en) 1990-12-07 1995-01-17 The Center For Innovative Technology Allosteric hemoglobin modifier compounds
US5648375A (en) 1990-02-12 1997-07-15 Virginia Commonwealth University Use of hydrophobic compounds and anesthetics in combination with allosteric hemoglobin modifiers
US5731454A (en) 1990-02-12 1998-03-24 Virginia Commonwealth University Allosteric modifiers of hemoglobin useful for decreasing oxygen affinity and preserving oxygen carrying capability of stored blood
US5432191A (en) 1990-02-12 1995-07-11 The Center For Innovative Technology Allosteric hemoglobin modifiers to decrease oxygen affinity in blood
US5049695A (en) 1990-02-12 1991-09-17 Center For Innovative Technology Allosteric hemoglobin modifiers
US5705521A (en) 1990-02-12 1998-01-06 The Center For Innovative Technology Use of allosteric hemoglobin modifiers in combination with radiation therapy to treat carcinogenic tumors
US5677330A (en) 1990-02-12 1997-10-14 The Center For Innovative Technology Medical uses of allosteric hemoglobin modifier compounds in patient care
US5290803A (en) 1990-02-12 1994-03-01 The Center Of Innovative Technology Using allosteric hemoglobin modifiers to decrease oxygen affinity in blood
US5591892A (en) 1990-02-12 1997-01-07 Center For Innovative Technology Allosteric modifiers of hemoglobin
US5872282A (en) 1990-12-07 1999-02-16 Virginia Commonwealth University Allosteric modifiers of hemoglobin
FR2677984B1 (fr) 1991-06-21 1994-02-25 Elf Sanofi Derives d'imidazoline n-substitues, leur preparation, les compositions pharmaceutiques en contenant.
US5260325A (en) 1991-08-19 1993-11-09 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking tertiary amides
US5258407A (en) 1991-12-31 1993-11-02 Sterling Winthrop Inc. 3,4-disubstituted phenols-immunomodulating agents
US5356904A (en) 1992-10-07 1994-10-18 Merck & Co., Inc. Carbostyril oxytocin receptor antagonists
WO1994013671A1 (en) 1992-12-04 1994-06-23 Janssen Pharmaceutica N.V. Antiallergic triazolobenzazepine derivatives
US5571813A (en) 1993-06-10 1996-11-05 Beiersdorf-Lilly Gmbh Fused pyrimidine compounds and their use as pharmaceuticals
US5395846A (en) 1993-06-25 1995-03-07 Rhone-Poulenc Rorer Pharmaceuticals Inc. Amino Bi- and tri-carbocyclic aklane bis-aryl squalene synthase inhibitors
FR2708608B1 (fr) 1993-07-30 1995-10-27 Sanofi Sa Dérivés de N-sulfonylbenzimidazolone, leur préparation, les compositions pharmaceutiques en contenant.
SG52229A1 (en) 1993-08-10 1998-09-28 Black James Foundation Gastrin and cck receptor ligands
US5426105A (en) 1993-09-24 1995-06-20 G.D. Searle & Co. Conformationally restricted angiotensin II antagonists
US5674879A (en) 1993-09-24 1997-10-07 G.D. Searle & Co. Compositions including and methods of using conformationally restricted angiotensin II antagonist
TW279860B (es) 1993-11-12 1996-07-01 Ciba Geigy Ag
DE4338784A1 (de) 1993-11-12 1995-05-18 Langhals Heinz Perylen-3,4-dicarbonsäureimide - neue hoch lichtechte Fluoreszenzfarbstoffe
GB9409150D0 (en) 1994-05-09 1994-06-29 Black James Foundation Cck and gastrin receptor ligands
US5795907A (en) 1994-05-27 1998-08-18 James Black Foundation Limited Gastin and CCK receptor ligands
DE69530081T2 (de) 1994-05-27 2003-12-24 James Black Foundation Ltd., London Gastrin- und cck-antagonisten
BR9610048A (pt) 1995-08-30 1999-07-06 Bayer Ag Acil amino salicilamidas
FR2741878B1 (fr) 1995-12-01 1998-01-09 Cird Galderma Composes biaromatiques portant un groupement adamantyl en ortho, compositions pharmaceutiques et cosmetiques les contenant et utilisations
TW359669B (en) 1995-12-15 1999-06-01 Otsuka Pharma Co Ltd Benzazepine derivatives
US6124289A (en) 1996-07-24 2000-09-26 Dupont Pharmaceuticals Co. Azolo triazines and pyrimidines
KR20010020201A (ko) 1997-04-22 2001-03-15 코센시스 인크 탄소고리 및 헤테로고리 치환된 세미카르바존 및 티오세미카르바존과 그들의 사용 방법
US6506783B1 (en) 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
US6521641B1 (en) 1998-10-08 2003-02-18 Allergan, Inc. Male anti-fertility agents
GB9902453D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
US6541477B2 (en) 1999-08-27 2003-04-01 Scios, Inc. Inhibitors of p38-a kinase
US6583183B2 (en) 1999-09-23 2003-06-24 Pharmacia Corporation Substituted n-phenyl-n-fused-benzyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity
AUPQ309399A0 (en) 1999-09-28 1999-10-21 Fujisawa Pharmaceutical Co., Ltd. Benzothiazoline derivatives
US6482829B2 (en) 2000-06-08 2002-11-19 Hoffmann-La Roche Inc. Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor
US7129242B2 (en) 2000-12-06 2006-10-31 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
US6833371B2 (en) 2001-11-01 2004-12-21 Icagen, Inc. Pyrazolopyrimidines
JP2003286171A (ja) 2002-03-28 2003-10-07 Sumitomo Pharmaceut Co Ltd Ｐａｒ阻害剤
AU2003226149A1 (en) 2002-04-05 2003-10-27 Merck & Co., Inc. Substituted aryl amides
BR0313041A (pt) 2002-07-29 2005-06-21 Hoffmann La Roche Compostos; composições farmacêuticas; método para o tratamento e/ou profilaxia de doenças que estão associadas à modulação dos receptores de cb1; e uso de compostos
US7186735B2 (en) 2002-08-07 2007-03-06 Sanofi-Aventis Deutschland Gmbh Acylated arylcycloalkylamines and their use as pharmaceuticals
PL376822A1 (pl) 2002-11-07 2006-01-09 Merck & Co., Inc. Pochodne fenyloalaniny jako inhibitory dipeptydylopeptydazy do leczenia lub zapobiegania cukrzycy
WO2004056744A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
WO2004078114A2 (en) 2003-02-28 2004-09-16 Encysive Pharmaceuticals Inc. Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-ii receptor antagonists.
EP1599482A4 (en) 2003-02-28 2008-10-01 Teijin Pharma Ltd PYRAZOLO1,5-A PYRIMIDINE DERIVATIVES
US7320989B2 (en) 2003-02-28 2008-01-22 Encysive Pharmaceuticals, Inc. Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
DK1615647T3 (da) 2003-04-11 2010-04-06 High Point Pharmaceuticals Llc Farmaceutisk anvendelse af kondenserede 1,2,4-triazoler
US20060094699A1 (en) 2003-04-11 2006-05-04 Kampen Gita Camilla T Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy
US20070270408A1 (en) 2003-04-11 2007-11-22 Novo Nordisk A/S Pharmaceutical use of substituted pyrazolo[1,5-a]pyrimidines
US7700583B2 (en) 2003-04-11 2010-04-20 High Point Pharmaceuticals, Llc 11β-hydroxysteroid dehydrogenase type 1 active compounds
US7501405B2 (en) 2003-04-11 2009-03-10 High Point Pharmaceuticals, Llc Combination therapy using an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders
EP2239012A3 (en) 2003-04-11 2011-06-15 High Point Pharmaceuticals, LLC Substituted amide derivatives and pharmaceutical uses thereof
US7915293B2 (en) 2003-05-30 2011-03-29 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
WO2005037199A2 (en) 2003-10-10 2005-04-28 Bristol-Myers Squibb Company Pyrazole derivatives as cannabinoid receptor modulators
KR100808742B1 (ko) 2004-03-11 2008-02-29 액테리온 파마슈티칼 리미티드 테트라하이드로피리도인돌 유도체
US20050261302A1 (en) 2004-04-29 2005-11-24 Hoff Ethan D Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their therapeutic application
US20060009918A1 (en) 2004-07-08 2006-01-12 Sanku Mallik Methods and materials for enhancing the effects of protein modulators
JP2008515956A (ja) 2004-10-12 2008-05-15 ノボ ノルディスク アクティーゼルスカブ １１β−ヒドロキシステロイドデヒドロゲナーゼ１型活性スピロ化合物
MX2007008238A (es) 2005-01-05 2007-08-17 Abbott Lab Derivados de adamantilo como inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa tipo 1.
CN102816081A (zh) 2005-01-05 2012-12-12 雅培制药有限公司 11-β-羟甾类脱氢酶1型酶的抑制剂
CN1736485A (zh) 2005-06-29 2006-02-22 上海美迪西生物医药有限公司 香草醛受体激动剂用于制备抗阿尔茨海默病产品的用途
EP1948190A2 (en) 2005-11-01 2008-07-30 Transtech Pharma Pharmaceutical use of substituted amides
KR20080069189A (ko) 2005-11-01 2008-07-25 트랜스테크 파르마, 인크. 치환된 아미드의 약학적 사용
JP5089185B2 (ja) 2006-02-02 2012-12-05 大塚製薬株式会社 コラーゲン産生抑制剤。
EP2007722A1 (en) 2006-03-21 2008-12-31 High Point Pharmaceuticals, LLC Adamantane derivatives for the treatment of the metabolic syndrome
EP2010479A1 (en) 2006-04-07 2009-01-07 High Point Pharmaceuticals, LLC 11 beta-hydroxysteroid dehydrogenase type 1 active compounds
CA2653098A1 (en) * 2006-06-13 2007-12-21 Med-El Elektromedizinische Geraete Gmbh Cochlear implant power system and methodology
JP2009539937A (ja) 2006-06-16 2009-11-19 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー 置換型ピペリジンカルボキサミドの医薬的使用
EP1878721A1 (en) 2006-07-13 2008-01-16 Novo Nordisk A/S 4-Piperidylbenzamides as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
JP2010519240A (ja) 2007-02-23 2010-06-03 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー １１−ベータ−ヒドロキシステロイドデヒドロゲナーゼの阻害剤としての、ｎ−アダマンチルベンズアミド
WO2008101885A1 (en) 2007-02-23 2008-08-28 High Point Pharmaceuticals, Llc N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase
JP2010519242A (ja) 2007-02-23 2010-06-03 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー 新規化合物
CN101679217A (zh) 2007-02-23 2010-03-24 高点制药有限责任公司 作为11β-羟基类固醇脱氢酶抑制剂的N-金刚烷基苯甲酰胺
US20100056600A1 (en) 2007-03-28 2010-03-04 Soren Ebdrup 11beta-hsd1 active compounds
ES2399912T3 (es) 2007-04-11 2013-04-04 High Point Pharmaceuticals, Llc Nuevos compuestos
JP2010526777A (ja) 2007-04-24 2010-08-05 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー 置換アミドの医薬用途
CN102223797A (zh) 2008-11-21 2011-10-19 高点制药有限责任公司 金刚烷基苯甲酰胺化合物

Also Published As

Publication number Publication date
JP2010520864A (ja) 2010-06-17
CA2679866A1 (en) 2008-09-18
WO2008110196A1 (en) 2008-09-18
BRPI0721430A2 (pt) 2013-01-08
CN101652359A (zh) 2010-02-17
EP2134705A1 (en) 2009-12-23
US8153798B2 (en) 2012-04-10
EA200970841A1 (ru) 2010-04-30
KR20100015414A (ko) 2010-02-12
AU2007349112A1 (en) 2008-09-18
IL200714A0 (en) 2010-05-17
US20100076041A1 (en) 2010-03-25

Similar Documents

Publication Publication Date Title
MX2009009623A (es) Inidol y bencimidazol amidas como inhibidores de la dehidrogenasa hidroxi-esteroide.
WO2007051811A3 (en) Pharmaceutical use of substituted amides
HK1140377A1 (en) Pharmaceutical use of substituted amides
WO2007051810A3 (en) Pharmaceutical use of substituted amides
WO2004089470A3 (en) New amide derivatives and pharmaceutical use thereof
WO2004089380A3 (en) Pharmaceutical use of fused 1,2,4-triazoles
EA200970791A1 (ru) N-АДАМАНТИЛБЕНЗАМИДЫ В КАЧЕСТВЕ ИНГИБИТОРОВ 11-β-ГИДРОКСИСТЕРОИДДЕГИДРОГЕНАЗЫ
MXPA05013224A (es) Piridinilcarbamatos como inhibidores de lipasa sensible a hormonas.
MY142589A (en) Benzimidazole derivatives : preparation and pharmaceutical applications
NO20092529L (no) Substituerte 2,3-dihydroimidazo[1,2-c]kinazolinderivater som er anvendbare for behandling av hyperproliferative forstyrrelser og sykdommer assosiert med angiogenese
MX2014003408A (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][ 1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la beta-secretasa 1 (bace1).
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
SG151329A1 (en) Amido compounds and their use as pharmaceuticals
MY143795A (en) Tetrahydropyridoindole derivatives
NZ612000A (en) Bicyclo[3.2.1]octyl amide derivatives and uses of same
DK1778680T3 (da) Spirocykliske cyclohexaderivater
MX2013008478A (es) 1, 4 riazepinas/sulfonas como inhibidores de beta secretasa 1 (base1) y/o beta secretasa 2 (bace2).
GB2427405A (en) Novel hydroxamates as therapeutic agents
PH12014502623B1 (en) Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors
ATE531703T1 (de) Benzochromenderivate
EP1868613A4 (en) POLYMORPHOS OF 3-O- (3 ', 3'-DIMETHYLSUCCINYL) BETULINIC DI-N-METHYL-D-GLUCAMINE
UA99638C2 (ru) Оксазолидиноны для лечения и/или профилактики сердечной недостаточности
GB0522908D0 (en) Therapeutic agents
EA201290485A1 (ru) Производные бензамида
MX2010008586A (es) Amidas de acido 3-(4-fluorofenil)-3-hidroxi-2-amino-propionico y compuestos relacionados que tienen actividad analgesica.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal